Ergomed's PrimeVigilance wins Queen's Award for Enterprise
Ergomed said PrimeVigilance, its pharmacovigilance, regulatory and medical information service provider, had been awarded the Queen's Award for Enterprise for the second time following its first award in 2014.
Ergomed's PrimeVigilance had received the 2019 Queen's Award for International Trade in recognition of its year-on-year outstanding services in the drug safety sector for its global customer base, the company said.
'As an International Trade winner, PrimeVigilance has demonstrated substantial growth in overseas markets and commercial success, further cementing its place as a global leader in pharmacovigilance,' it added.
'This prestigious accolade recognises the Company's continued year-on-year international growth and reinforces Ergomed's position as a leading provider of services to the pharmaceutical industry.'
'The global pharmacovigilance market is forecast to grow to more than $8 billion by 2024 from around $3 billion in 2015, with contract outsourcing forecast to expand from around 30% of the market in 2015 to approximately 50% in 2024, the company said, citing information from Global Market Insights 2017.